【hoco captions with friends】What Should You Know About The Future Of AstraZeneca PLC’s (LON:AZN)?
After AstraZeneca PLC’s (
LON:AZN
) earnings announcement in September 2018,hoco captions with friends analysts seem cautiously optimistic, with profits predicted to increase by 10.0% next year against the past 5-year average growth rate of 7.6%. With trailing-twelve-month net income at current levels of US$3.0b, we should see this rise to US$3.3b in 2020. I will provide a brief commentary around the figures and analyst expectations in the near term. For those interested in more of an analysis of the company, you can
research its fundamentals here
.
View our latest analysis for AstraZeneca
Can we expect AstraZeneca to keep growing?
Longer term expectations from the 25 analysts covering AZN’s stock is one of positive sentiment. Given that it becomes hard to forecast far into the future, broker analysts tend to project ahead roughly three years. To understand the overall trajectory of AZN’s earnings growth over these next fews years, I’ve fitted a line through these analyst earnings forecast to determine an annual growth rate from the slope.
LSE:AZN Future Profit January 1st 19
From the current net income level of US$3.0b and the final forecast of US$6.5b by 2022, the annual rate of growth for AZN’s earnings is 27%. EPS reaches $3.99 in the final year of forecast compared to the current $2.37 EPS today. In 2022, AZN’s profit margin will have expanded from 13% to 22%.
Next Steps:
Future outlook is only one aspect when you’re building an investment case for a stock. For AstraZeneca, there are three relevant aspects you should look at:
Financial Health
: Does it have a healthy balance sheet? Take a look at our
free balance sheet analysis with six simple checks
on key factors like leverage and risk.
Valuation
: What is AstraZeneca worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The
intrinsic value infographic in our free research report
helps visualize whether AstraZeneca is currently mispriced by the market.
Other High-Growth Alternatives
: Are there other high-growth stocks you could be holding instead of AstraZeneca? Explore
our interactive list of stocks with large growth potential
to get an idea of what else is out there you may be missing!
To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at
.
View comments
-
HealthEquity (HQY) Lags Q1 Earnings and Revenue EstimatesIs the Options Market Predicting a Spike in Seagate (STX) Stock?NEWSMAKER-So near yet so far for Malaysia's AnwarSherwin-Williams (SHW): Strong Growth And Abundant PotentialHow Does Ensign Group's (NASDAQ:ENSG) P/E Compare To Its Industry, After The Share Price Drop?Here's How Long It Took Apple To Reach A $100B Market CapAkoustis Reports Third Quarter FY20 ResultsDorian LPG: Q2 Earnings InsightsAmericans See Record Fall in Consumer Spending, Savings SoarCheniere seeks U.S. permission to put Oklahoma Midship natgas pipe in service
下一篇:Wall Street falls as coronavirus shreds U.S. payrolls
- ·NYSE: REZI Shareholder Notice: Lawsuit against Resideo Technologies, Inc. announced by Shareholders Foundation
- ·As coronavirus misinformation spreads on social media, Facebook removes posts
- ·Capstar Financial Holdings, Inc. (NASDAQ:CSTR) Passed Our Checks, And It's About To Pay A US$0.05 Dividend
- ·Drone Delivery Canada Begins Flights For First Paying Customer
- ·E-mini Dow Jones Industrial Average (YM) Futures Technical Analysis – Strong Over 27741, Weak Under 27400
- ·Are Options Traders Betting on a Big Move in Penn National (PENN) Stock?
- ·Is Ivy Small Cap Growth Y (WSCYX) a Strong Mutual Fund Pick Right Now?
- ·Hydro66 Announces Additional Advance Under Convertible Loan
- ·Harpoon Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
- ·NEWSMAKER-So near yet so far for Malaysia's Anwar
- ·Survey Results: Investors Have No Idea Where The Market Is Headed Next
- ·A Sliding Share Price Has Us Looking At Rexnord Corporation's (NYSE:RXN) P/E Ratio
- ·Memgen Announces Addition to Board of Directors
- ·The Gross Law Firm Announces Class Actions on Behalf of Shareholders of WORX, CLNY and CCL
- ·AP Top Extended Financial Headlines at 9:52 p.m. EST
- ·A Trio of Strong Performers to Consider
- ·PharmaCielo Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In PharmaCielo Ltd. To Contact The Firm
- ·IBM Stock Falls 4%
- ·Are Options Traders Betting on a Big Move in Penn National (PENN) Stock?
- ·Big cash holdings in Europe signal unease over stock market outlook
- ·Morgan Stanley Deboards From Cruise Lines, Bearish On Carnival, Norwegian And Royal Caribbean
- ·5 High-Yield Stocks to Defy Coronavirus-Led Crisis in April
- ·Sick of Roaming Fees? Now Your Carrier Is Hurting Too
- ·Aligos Therapeutics Appoints Lesley Ann Calhoun as Chief Financial Officer
- ·Knowles (KN) Q1 Earnings Beat Estimates, Revenues Down Y/Y
- ·Wall Street dives 4% as virus pandemic fears intensify
- ·Number of voting rights as of November 30,2020
- ·Newmont (NEM) in Focus: Stock Moves 6.2% Higher
- ·Skyworks Solutions (SWKS) Matches Q2 Earnings Estimates
- ·U.S. CDC reports 1,827,425 coronavirus cases
- ·Genesco (GCO) Gains But Lags Market: What You Should Know
- ·Sanofi to Withdraw Zantac After FDA Warns of Carcinogens
- ·How Does Credit Acceptance's (NASDAQ:CACC) P/E Compare To Its Industry, After Its Big Share Price Gain?
- ·Media Stock Earnings Roster This Week: DISCA, FOXA & More
- ·Why Uranium Markets Are Gaining Interest
- ·Business owners contend with threat, reality of coronavirus